WP-1048 is under clinical development by Worg Pharmaceuticals Hangzhou and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect WP-1048’s likelihood of approval (LoA) and phase transition for Grass Pollen Allergy took place on 29 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their WP-1048 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

WP-1048 overview

WP-1048 a recombinant protein (hypoallergenic grass pollen vaccine) is under development for the treatment of grass-pollen allergy. It is a third generation grass pollen allergy. It is a mixture of four recombinant proteins consists of BM321, BM322, BM325 and BM326. It is administered by subcutaneous route. The drug candidate is developed based on peptide carrier fusion protein technology (PCFiT).

Worg Pharmaceuticals Hangzhou overview

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential. It is headquartered in Hangzhou, Zhejiang, China.

Quick View WP-1048 LOA Data

Report Segments
  • Innovator
Drug Name
  • WP-1048
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Immunology
Key Developers
  • Sponsor Company: Worg Pharmaceuticals Hangzhou
  • Originator: Biomay
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.